Filing Flows › Pelthos Therapeutics (PTHS) › Q4 2025
Pelthos Therapeutics (PTHS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 19, 2026
Pelthos Therapeutics (PTHS) reported revenue of $9.4M for the fourth quarter 2025 (Q4 2025) and +27% from the quarter before. Operating margin was -127.8%, net loss $21.7M (230.7% of revenue).
Pelthos Therapeutics, Q4 2025: revenue $9.4M, operating margin -127.8%, net loss $21.7M, operating cash flow −$6.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.4M | +27% | — |
| Operating profit | −$12.0M | — | — |
| Net earnings | −$21.7M | — | — |
| Operating cash flow | −$6.3M | — | — |
What changed
Revenue was $9.4M in Q4 2025, up 27% from the previous quarter.
Operating costs exceeded revenue by $12.0M, an operating margin of -127.8%. The quarter ended with a net loss of $21.7M, wider than the previous quarter's $16.2M loss. Net interest and other expense of $16.6M was the main reason.
Operating cash flow was −$6.3M. Non-cash charges added back $1.8M of share-based compensation. Working capital and other items added $13.6M.
Questions
What was Pelthos Therapeutics' revenue in the fourth quarter 2025?
Pelthos Therapeutics (PTHS) reported revenue of $9.4M for the fourth quarter 2025 (Q4 2025) and +27% from the quarter before.
Was Pelthos Therapeutics profitable in the fourth quarter 2025?
Operating loss was $12.0M (-127.8% of revenue) and net loss $21.7M.